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Summary 
The intestinal  inflammatory bowel disease (IBD) are a group of inflammatory patholo-
gies of the digestive line with chronicity and recurrent characteristics. The IBDs mostly 
recognized are the ulcerative colitis and Crohn’s disease; they are more frequent in 
the industrialized countries and among the caucasian populations that among those 
africans or oriental. The secondary artropaties to IBD recognize a multifactorial gene-
sis in subjects predisposed as a result genetically of environmental factors; a funda-
mental role of the intestinal dysbiosis they are hypothesized. 
Introduction 
The predominant etiological opinion is that the IBDs recognize a multifactorial genesis. 
Currently the more accredited pathogenetic hypotheses foresee the presence of three 
principal factors: genetic susceptibility; environmental factors; immune-pathogenetic 
factors [1,2]; instigating events that determine an alteration of the intestinal immune-
regulation and his permeability with consequent inflammatory damage [3-5]. The ele-
vated frequency of agreement for the illness among homozygote twins points out the 
importance of genetic factors in to determine the family distribution. The evidence of 
an agreement among monozygotic and dizygotic twins respectively of 37% and of 7% 
it corresponds to areduced penetrance of the genotype and it shows the importance of 
the environmental factors in the development of the illness [6,7]. Studies of linkage of 
the whole genome have allowed to identify different locus of susceptibility for the 
IBDs.The data most meaningful respect to an association between environmental fac-
tors and IBD they are those related to 
the smoke of cigarette, to the appendec-
tomy, the use of oral contraceptives in 
the women and use of FANS, the viral 
infections as the measles, in the infancy 
and some constituent ones of the diet, 
what the refined sugars and the unsatu-
rated fats [8-10]. The eubiosis loss, nec-
essarily determines the growth of manu-
facturing microorganisms of specific 
metabolic components, to toxic action, 
able to activate the immune local system 
(GALT) and therefore to bait an inflam-
matory reaction to load of the mucous 
same. You observes therefore a decre-
ment of the Lactobacillus and an increase 
of the concentration of pathogen micro-
organisms, that expounds a for-
inflammatory effect on the mucous one. 
In the subjects affections from IBD it is 
assisted to the cleavage of the mucus-
epithelial layer, whose integrity is essen-
tial for the defense of the mucous colic 
[11-13]. The arthritis is the more com-
mon extra-intestinal demonstration, with 
a 30% frequency and it meaningfully in-
fluences the quality of life and the mor-
bidity of the subjects that are stricken of 
it [14-20]. L' altered operation of the 
ability of migration and homing of the 
intestinal lymphocytes, such that the 
same are able of to reach the articula-
tions, favored by the deregulate expres-
sion of the molecules of adhesion of the 
vascular endothelial, it is supposed both 
at the base of the pathogenetic trial re-
sponsible of the secondary peripheral 
arthritis to IBD. 
 
Materials and Methods 
The clinical and bio-umoralis evaluations 
performed on two groups of patients 
have the purpose to show the greatest 
effectiveness of the employment of pro-
biotic mixtures in association to the con-
ventional therapy for the treatment of 
the IBDs in comparison to the only stan-
dard treatment. We have we will only 
consider the patients with secondary ar-
ticular demonstrations to IBD with light, 
moderate or severe degree of activity 
appraising the effectiveness of the com-
plementary treatment with probiotics in 
comparison to the standard therapy 
without probiotics. The 18 patients of the 
group (A) have received a FANS 
(Diclofenac - 75 mgs im/die in only ad-
ministration for 10 days) associated to 
the mesalazina (compressed from 800 
mgs, a pill twice a day in the light forms 
and a pill three times to day in the mod-
erate forms; in these last ones you can 
be added in phase of exacerbation of the 
symptomatology a bland treatment with 
cortisones in the form of prednisone in 
pills from 25 mgs). The 19 patients of the 
group (B) have received the experimental 
treatment with probiotics, or a mixture 
constituted by Lactobacillus Salivarius, 
Lactobacillus Acidophilus, Bifidobacterium 
Bifidum and Vitamin C (ACRONELLE®- 1 
capsule from 0,460 grs.), the all always 
in association to two capsules a day of 
mesalazina and FANS.The recruited pa-
tients have been thirty-seven (37) in an 
inclusive temporal interval between Janu-
ary 2010 and December 2013. The 
enlisted subjects already possessed diag-
nosis of IBD and in partnership secon-
dary arthropathy. The patients have par-
ticipated in our clinical study performed 
the University General Hospital "Paolo 
Giaccone" of Palermo, Italy, with the in-
volvement of the Orthopedic and Trau-
matology Clinic. During the refuge and 
with follow-up to every months for the 
first 4 months and then every two 
months, all the patients have clinically 
been appraised with indexes what the 
Disease Index Score for the IBDs and the 
WOMAC score for the peripheral ar-
thropathy. They have been, besides per-
formed bio-umorali sex aminations to 
dose the VES, the PCR and the leuko-
cytes. 
The population object of study has been 
selected following well precise criterions 
of inclusion or diagnosis of IBD and in 
partnership secondary arthropathy, the 
data have been filed then using software 
for the management of electronic spread-
sheets. Statistics analysis has been con-
ducted with software SPSS, performing 
special tests we have verified if the data 
were distributed according to a normal 
distribution and therefore calculating the 
difference of the data using the paramet-
ric test of the T-test with limits of confi-
dence to 95%. 
 
IBD AND PERIPHERAL ARTHRITIS, p. 113 EMBJ, 11 (15), 2016 — www.embj.org 
Result 
Statistics analysis has brought both for 
the group A, both for the group B, an 
improvement in the post treatment 
(survey to months. from the beginning) 
of the considered parameters: WOMAC 
score (Figure 1), PCR (Figure 2), VES 
(Figure 3) and Leukocytes (Figure 4) 
with H0:Me1=Me2 vs H1:Me1≠Me2 and 
meaningful difference (p<.05) among 
the two groups object of study. 
The comparison of the group dates for 
the values WOMAC, mean 38 in the 
group A and 21,4 in the group B, has 
shown difference (P <.05) to point out a 
clinical and functional improvement of 
the articulations involved in the patients 
which the probiotics have been adminis-
tered (Figure 1). 
The comparison of the data for the values 
of PCR, mean 27,55 in the group A and 
15 in the group B, has shown with mean-
ingfulness (P <.05) that the patients es-
says with probiotics have improved the 
owed general inflammatory condition 
both to the primary pathology IBD but 
also to the articular inflammation in how 
much the improvement is simultaneous 
with the values of the staircase WOMAC 
(Figure 2). 
The comparison of the group dates both 
for the values of VES, mean 36,7 in the 
group A and 17,4 in the group B, that for 
the values of WBC, mean 16,3 in the 
group A and 10 in the group B, has 
shown differencemeaningfulness (P <.05) 
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Figure 1: Results of the tests of normalcy and the T-test for the values of the 
WOMAC scale; (IC to 95%; H0:Me1=Me2 against H1:Me1 .Me2). Groups of differ-
ent data meaningfully to point out the substantial improvement of the patients of 
the group B treated with probiotics. (P <.05).  
Figure 2: Results of the tests of normalcy and the T-test for the values of the C -  
Reactive Protein; (IC to 95%; H0:Me1=Me2 against H1:Me1 .Me2). Values of C - 
Reactive Protein post-therapy mostly meeting places in the patients of the group B 
treated with probiotics. (P <.05).  
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to point out a clinical improvement and 
of the general inflammatory condition in 
the patients which the probiotics have 
been administered, also nevertheless a 
condition of inflammation well born sub-
clinic remains from the patients that it is 
typical of the IBDs (Figure 3 and 4). 
 
Conclusions 
The primary objective of our study was 
to appraise the entity of the improve-
ment of the articular picture recording 
the conditions of the patients at the end 
of the follow-up (keeping in mind of clini-
cal evaluations and) comparing the final 
results of the two groups in study. The 
gotten results have sometimes been su-
perior to our attended, already to a first 
clinical analysis and also without an ob-
jective evaluation of the picked data, in 
fact, the benefit was evident gotten by 
the patients by the association of the 
probiotics to the standard treatment, evi-
dence that has been proven then by the 
statistic analysis of the data [21-
23].Analyzing the final results of both the 
groups is deduced as the subjects essays 
with the addition of the probiotics (Group 
B) introduces a best answer to the stan-
dard therapy with meaningfulness 
(p<.05) in comparison to the subjects 
that have not profited any probiotics, in 
how much the use of the mixture probi-
otics strengthens the already positive ef-
fects of the anti-inflammatory. The 
analysis of this group of patients with 
Figure 4: Results of the tests of normalcy and the T-test for the values of the WBCs; 
(IC to 95%; H0:Me1=Me2 against H1:Me1 .Me2). Values of WBC post-therapy de-
creased in the patients of the group B treated with probiotics. (P <.05).  
Figure 3: Results of the tests of normalcy and the T-test for the values of the       
Eritrocite Sedimentation Rate; (IC to 95%; H0:Me1=Me2 against H1:Me1 .Me2). 
Values of Eritrocite Sedimentation Rate post-therapy mostly decreased in the pa-
tients of the group B treated with probiotics. (P <.05).  
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secondary arthropathy to IBD shows that 
the behavior and the elapsed clinical it is 
tightly dependent from the entity from 
the intestinal inflammation, motive for 
which if we intervene on the intestinal 
microbiota so that to resolve the dysbio-
sis we can favor a notable clinical im-
provement both of the secondary arthri-
tis to the IBDs and of the other demon-
strations extraintestinal, both of the 
same intestinal illness [24,25]. 
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